Merger Agreement (Details) $ / shares in Units, $ in Thousands |
Apr. 15, 2025
USD ($)
$ / shares
shares
|
Dec. 31, 2025
$ / shares
shares
|
Dec. 31, 2024
$ / shares
shares
|
|---|---|---|---|
| Merger Agreement | |||
| Common stock, par value (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |
| Common stock, shares authorized (in shares) | 150,000,000 | 58,251,629 | |
| Cara Therapeutics, Inc. | |||
| Merger Agreement | |||
| Stock split conversion ratio | 0.333 | ||
| Common stock, shares authorized (in shares) | 150,000,000 | ||
| Legacy Tvardi | |||
| Merger Agreement | |||
| Common stock, par value (in dollars per share) | $ / shares | $ 0.001 | ||
| Number of converted shares upon closing of merger | 6,539,404 | ||
| Cara net assets acquired | $ | $ 23,873 | ||
| Issuance of common stock upon the conversion of Convertible Notes (in shares) | 1,265,757 | ||
| Percentage of interest held in combined company after the merger | 84.50% | ||
| Goodwill | $ | $ 0 |
| X | ||||||||||
- Definition The percentage of interest held. No definition available.
|
| X | ||||||||||
- Definition Number of shares issued upon closing of merger. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|